Insmed Is Maintained at Buy by Stifel

Insmed Is Maintained at Buy by Stifel

Dow JonesMay 31 09:34 ET

Insmed Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 16.49% Stifel $39 → $67 Maintains Buy 05/29/2024 16.49% TD Cowen $45 → $67 Maintains Buy 05/29/

BenzingaMay 31 09:22 ET

Express News | Insmed Inc : Stifel Raises Target Price to $67.00 From $39.00

ReutersMay 31 06:53 ET

Insmed Insider Sold Shares Worth $2,215,081, According to a Recent SEC Filing

Michael Alexander Smith, Chief Legal Officer, on May 28, 2024, sold 44,722 shares in Insmed (INSM) for $2,215,081. Following the Form 4 filing with the SEC, Smith has control over a total of 88,828 sh

MT NewswiresMay 31 03:42 ET

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Insmed (INSM)

TipRanksMay 30 22:20 ET

Top Gap Ups and Downs on Thursday: CRM, SAP, NOW and More

Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.

moomoo NewsMay 30 21:22 ET